ERBB2 and early-onset autosomal dominant Alzheimer disease: Tyrphostin AG 825 is a selective, ATP-competitive ErbB2 inhibitor that inhibits tyrosine phosphorylation, as a potential anti-Alzheimer’s disease drug, it has been confirmed to have effects on anticancer, accelerating neutrophil apoptosis.